• SB202190: Precision p38 MAP Kinase Inhibitor for Research Us

  2026-05-29

  SB202190 is a potent, ATP-competitive p38 MAP kinase inhibitor widely utilized in inflammation and cancer therapeutics research. It offers nanomolar selectivity for p38α and p38β isoforms, enabling precise dissection of MAPK signaling in cellular and animal models. The compound's robust biochemical profile and reproducible activity underpin its value for apoptosis, cytokine modulation, and neuroprotection studies.

• Honokiol: Applied Workflows for NF-κB Inhibition in Cancer R

  2026-05-29

  Honokiol, a potent NF-κB pathway inhibitor and antiangiogenic compound, empowers researchers with precise control over oxidative stress and inflammation in advanced cancer models. Discover optimized experimental workflows, troubleshooting insights, and the translational value of Honokiol from APExBIO for dissecting tumor microenvironment dynamics.

• QPRT Drives Breast Cancer Invasion via Purinergic and Myosin

  2026-05-28

  This study reveals that quinolinate phosphoribosyltransferase (QPRT) enhances breast cancer cell invasiveness by activating a purinergic signaling cascade leading to myosin light chain phosphorylation. Functional reversal by P2Y11 antagonism highlights the pathway's mechanistic significance and provides a rational framework for targeting QPRT-P2Y11 signaling in cancer research.

• Cycloheximide: Precision Protein Biosynthesis Inhibitor Work

  2026-05-28

  Cycloheximide empowers researchers to dissect protein turnover and apoptosis mechanisms with temporal precision. Its acute, reversible inhibition of eukaryotic translation enables advanced workflows in cell fate analysis, neuroprotection, and mechanistic apoptosis assays, setting industry standards for reproducibility and clarity.

• Epoxomicin: Precision Proteasome Inhibitor for Pathway Resea

  2026-05-27

  Epoxomicin’s irreversible, selective inhibition of the 20S proteasome empowers researchers to dissect ubiquitin-proteasome pathway dynamics with unparalleled specificity. This guide translates bench-proven workflows and troubleshooting strategies into actionable best practices for protein degradation assays, ER stress modeling, and neurodegenerative disease research.

• Maternal Deltamethrin Impairs Offspring Memory via p53-Ferro

  2026-05-27

  This study uncovers how maternal exposure to deltamethrin during pregnancy and lactation impairs hippocampal learning and memory in male offspring by triggering p53-mediated ferroptosis in the hippocampus. The mechanistic insights highlight the SLC7A11/GPX4 axis as a key target for neuroprotection and open new avenues for mitigating environmental neurotoxicant effects on developing brains.

• WNT5a/GSK3/β-catenin Axis Regulates FAP Adipogenesis in Musc

  2026-05-26

  This study establishes the canonical WNT5a/GSK3/β-catenin pathway as a central regulator of adipogenic differentiation in skeletal muscle fibro/adipogenic progenitors (FAPs). By integrating pharmacological, single-cell, and transcriptomic approaches, the authors reveal how modulation of this pathway can prevent pathological fat infiltration, offering new avenues for muscle regeneration research.

• Tetraethylammonium Chloride: Insights into β-Cell K+ Channel

  2026-05-26

  Explore Tetraethylammonium chloride’s pivotal role in advanced ion channel and vascular research, with a unique focus on pancreatic β-cell K+ channel modulation. This article delivers deeper mechanistic analysis and practical guidance for integrating TEAC into cutting-edge assay design.

• KPT-330 (Selinexor): Deep Mechanisms and Translational Impac

  2026-05-25

  Explore KPT-330 (Selinexor), a selective CRM1 inhibitor, through a mechanistic and translational lens. This article uniquely dissects its molecular actions and preclinical impact, guiding cancer research with advanced insights.

• Applied Use-Cases of (-)-Norepinephrine (+)-bitartrate in Ca

  2026-05-25

  (-)-Norepinephrine (+)-bitartrate is the gold-standard adrenergic agonist for modeling cardiovascular dysfunction and adrenergic signaling in both in vivo and in vitro systems. This article delivers scenario-driven workflows, troubleshooting guidance, and comparative insights to empower reproducible, high-impact cardiovascular and metabolic research.

• Vascular Effects of JAK Inhibitors on Endothelial Cells Unde

  2026-05-24

  This study systematically compares the vascular effects of multiple JAK inhibitors, including tofacitinib citrate (CP-690550 citrate), on endothelial cells exposed to inflammatory cytokines. The findings highlight both the shared anti-inflammatory actions and important differences in modulation of adhesion molecules, coagulation pathways, and cytotoxicity, informing the design and interpretation of cardiovascular and immune regulation research.

• Topotecan in Precision Oncology: Translational Insights and

  2026-05-23

  Explore Topotecan's distinct role in precision oncology, with a focus on translational research, mechanistic depth, and optimized protocols for apoptosis induction and pediatric tumor models. This article offers unique insights and evidence-backed recommendations for cancer research.

• BAPTA-AM: Cell-Permeable Calcium Chelator for Precision Assa

  2026-05-22

  Leverage BAPTA-AM for high-resolution control of intracellular Ca²⁺, unlocking advanced workflows in apoptosis, neuroprotection, and calcium signaling research. APExBIO's BAPTA-AM combines rapid cell permeability with selective chelation and dual ion channel modulation, enabling robust, reproducible experiments across cell biology domains.

• AhR Activation Mitigates Acute Pancreatitis via RBX1/HSF1 Pa

  2026-05-22

  Fang et al. reveal that aryl hydrocarbon receptor (AhR) activation alleviates acute pancreatitis in mice by modulating the RBX1/HSF1 pathway, specifically protecting tight junction integrity. Their mechanistic findings clarify how AhR orchestrates immune and epithelial responses, with implications for translational models of inflammation.

• BMS 599626 Dihydrochloride: Reliable EGFR/ErbB2 Inhibition i

  2026-05-21

  This article provides scenario-driven, evidence-based guidance for deploying BMS 599626 dihydrochloride (SKU B5792) in key cancer and senescence workflows. It addresses real-world assay reproducibility, data interpretation, and vendor selection, supported by quantitative data and peer-reviewed references. Researchers gain actionable insights for selecting and optimizing this selective EGFR and ErbB2 inhibitor.

460 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page